Loading: 100%
FIVE PRIME THERAPEUTICS INC logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 195 (as per Q3 2016)no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker FPRXno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 17015304560
datesClosing price (adj.)
13.10.201743.44
11.10.201740.97
04.10.201737.59
27.09.201737.20
20.09.201735.74
13.09.201735.45
06.09.201732.05
30.08.201731.94
23.08.201729.61
16.08.201728.51
09.08.201728.51
02.08.201727.07
26.07.201730.73
19.07.201729.21
12.07.201729.36
05.07.201731.73
27.06.201730.56
20.06.201729.58
13.06.201730.40
06.06.201730.12
30.05.201728.22
23.05.201729.81
16.05.201730.77
09.05.201730.07
02.05.201732.29
25.04.201734.42
18.04.201732.97
11.04.201734.07
04.04.201735.34
28.03.201735.28
21.03.201737.04
14.03.201739.76
07.03.201741.33
28.02.201745.87
21.02.201746.70
14.02.201746.03
07.02.201745.38
31.01.201745.81
24.01.201743.88
17.01.201747.51
10.01.201751.78
03.01.201748.60
27.12.201651.20
19.12.201651.66
12.12.201651.17
05.12.201659.39
28.11.201658.64
21.11.201658.72
14.11.201657.76
07.11.201650.00
31.10.201648.53
24.10.201649.03
17.10.201647.22
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
43.44n/a
Market Capitalisation
in million USD
1,236n/a
Enterprise Value
in million USD
795n/a
Common Shares Outstanding
as per Oct 31, 2016
28,441,594n/a
Preferred Shares Outstanding
as per Oct 31, 2016
n/a
Average Basic Shares Outstanding
TTM
26,609,750n/a
Average Diluted Shares Outstanding
TTM
27,035,000n/a
Index Membership
n/a
Business Summary
Five Prime Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in discovering & developing novel protein therapeutics to improve lives of patients with serious diseases.
no data available
Key Financials & Ratios (all figures TTM as per Sep 30, 2016, million USD, full statements further below)
Profit & Loss
Revenues 386n/a
Gross Profit 386n/a
Operating Income 266n/a
EBITDA 268n/a
Net Profit 251n/a
Balance Sheet
Cash and Cash Equivalents 441n/a
Receivables 0n/a
Total Current Assets 454n/a
PP&E 5n/a
Total Assets 465n/a
Accounts Payable 1n/a
Current Debt 0n/a
Total Current Liabilities 39n/a
Long-Term Debt 0n/a
Total Liabilities 61n/a
Total Equity 404n/a
Cash Flow
Depreciation & Amortisation 2n/a
Change in Working Capital -14n/a
Operating Cash Flow 269n/a
Net Change in PP&E and Intangibles -3n/a
Investing Cash Flow -245n/a
Dividends Paid 0n/a
Financing Cash Flow -5n/a
Total Change in Cash 19n/a
Free Cash Flow 233n/a
Profitability Ratios
Gross Margin 100.0%n/a
Operating Margin 69.0%n/a
Net Profit Margin 64.9%n/a
Return on Equity 62.0%n/a
Return on Assets 53.9%n/a
Per Share Figures
Basic EPS 9.42n/a
Diluted EPS n/a
Sales per Share 14.50n/a
Book Value per Share 15.18n/a
FCF per Share 8.77n/a
Dividends per Share 0.00n/a
Price Multiples
Price to Earnings Ratio 4.61n/a
Price to Sales Ratio 3.00n/a
Price to Book Value 2.86n/a
Price to Free Cash Flow 4.95n/a
Valuation Metrics
EV/EBITDA 2.97n/a
EV/Sales 2.06n/a
Book to Market Value 0.33n/a
Other Ratios
Current Ratio 1,159.9%n/a
Liabilities to Equity Ratio 15.1%n/a
Debt to Assets Ratio 0.0%n/a
Profit & Loss StatementP&L data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '11FY '12FY '13FY '14FY '15
Revenue
65
10
14
19
380
Sales & Services Revenue
0
0
0
0
0
Financing Revenue
0
0
0
0
0
Other Revenue
0
0
0
0
0
Cost of revenue
0
0
0
0
0
Cost of Goods & Services
0
0
0
0
0
Cost of Financing Revenue
0
0
0
0
0
Cost of Other Revenue
0
0
0
0
0
Gross Profit
65
10
14
19
380
Other Operating Income
0
0
0
0
0
Operating Expenses
-45
-38
-43
-57
-93
Selling, General & Administrative
-11
-9
-10
-14
-23
Selling & Marketing
0
0
0
0
0
General & Administrative
0
0
0
0
0
Research & Development
-34
-29
-33
-43
-70
Depreciation & Amortization
0
0
0
0
0
Provision For Doubtful Accounts
0
0
0
0
0
Other Operating Expense
0
0
0
0
0
Operating Income (Loss)
20
-28
-29
-38
287
Non-Operating Income (Loss)
0
0
1
0
0
Interest Expense, net
0
0
0
0
0
Interest Expense
0
0
0
0
0
Interest Income
0
0
0
0
0
Other Investment Income (Loss)
0
0
0
0
0
Foreign Exchange Gain (Loss)
0
0
0
0
0
Income (Loss) from Affiliates
0
0
0
0
0
Other Non-Operating Income (Loss)
0
0
0
0
0
Pretax Income (Loss), Adjusted
20
-28
-29
-37
287
Abnormal Gains (Losses)
0
0
0
0
0
Acquired In-Process R&D
0
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
0
Abnormal Derivatives
0
0
0
0
0
Disposal of Assets
0
0
0
0
0
Early extinguishment of Debt
0
0
0
0
0
Asset Write-Down
0
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
0
Sale of Business
0
0
0
0
0
Legal Settlement
0
0
0
0
0
Restructuring Charges
0
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
0
Insurance Settlement
0
0
0
0
0
Other Abnormal Items
0
0
0
0
0
Pretax Income (Loss)
20
-28
-29
-37
287
Income Tax (Expense) Benefit, net
0
0
0
0
-38
Current Income Tax
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
Tax Allowance/Credit
0
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
0
Income (Loss) from Continuing Operations
20
-28
-29
-37
250
Net Extraordinary Gains (Losses)
0
0
0
0
0
Discontinued Operations
0
0
0
0
0
XO & Accounting Charges & Other
0
0
0
0
0
Income (Loss) Including Minority Interest
20
-28
-29
-37
250
Minority Interest
-19
0
0
0
0
Net Income
1
-28
-29
-37
250
Preferred Dividends
0
0
0
0
0
Other Adjustments
0
0
0
0
0
Net Income Available to Common Shareholders
1
-28
-29
-37
250
Remarks
restated on Mar 26, 2014 n/a
calculated values,
restated on Mar 18, 2015 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
Balance SheetBS data quality: 96% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '11FY '12FY '13FY '14FY '15
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
38
76
149
517
Cash & Cash Equivalents
n/a
11
8
15
150
Short Term Investments
n/a
27
68
134
367
Accounts & Notes Receivable
n/a
0
0
0
4
Accounts Receivable, Net
n/a
0
0
0
0
Notes Receivable, Net
n/a
0
0
0
0
Unbilled Revenues
n/a
0
0
0
0
Inventories
n/a
0
0
0
0
Raw Materials
n/a
0
0
0
0
Work In Process
n/a
0
0
0
0
Finished Goods
n/a
0
0
0
0
Other Inventory
n/a
0
0
0
0
Other Short Term Assets
n/a
1
2
2
7
Prepaid Expenses
n/a
1
2
2
7
Derivative & Hedging Assets
n/a
0
0
0
0
Assets Held-for-Sale
n/a
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
Income Taxes Receivable
n/a
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
Miscellaneous Short Term Assets
n/a
0
0
0
0
Total Current Assets
n/a
39
78
151
528
Property, Plant & Equipment, Net
n/a
5
4
4
5
Property, Plant & Equipment
n/a
0
0
0
0
Accumulated Depreciation
n/a
0
0
0
0
Long Term Investments & Receivables
n/a
0
0
0
0
Long Term Investments
n/a
0
0
0
0
Long Term Marketable Securities
n/a
0
0
0
0
Long Term Receivables
n/a
0
0
0
0
Other Long Term Assets
n/a
0
0
1
15
Intangible Assets
n/a
0
0
0
0
Goodwill
n/a
0
0
0
0
Other Intangible Assets
n/a
0
0
0
0
Prepaid Expense
n/a
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
15
Derivative & Hedging Assets
n/a
0
0
0
0
Prepaid Pension Costs
n/a
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
Investments in Affiliates
n/a
0
0
0
0
Miscellaneous Long Term Assets
n/a
0
0
1
0
Total Noncurrent Assets
n/a
5
4
4
20
Total Assets
n/a
44
82
156
548
Liabilities and owners' equity
Payables & Accruals
n/a
5 5023000
5 5361000
7 7245000
61 61091000
Accounts Payable
n/a
1 557000
0 348000
1 1096000
2 1894000
Accrued Taxes
n/a
0 0
0 0
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
0 0
0 0
Other Payables & Accruals
n/a
4 4466000
5 5013000
6 6149000
59 59197000
Short Term Debt
n/a
0 0
0 0
0 0
0 0
Short Term Borrowings
n/a
0 0
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
0 0
0 0
Other Short Term Liabilities
n/a
8 8061000
8 8462000
13 12570000
18 18277000
Deferred Revenue
n/a
7 7498000
8 8462000
13 12570000
18 18277000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
1 563000
0 0
0 0
0 0
Total Current Liabilities
n/a
13 13084000
14 13823000
20 19815000
79 79368000
Long Term Debt
n/a
0 0
0 0
0 0
0 0
Long Term Borrowings
n/a
0 0
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
0 0
Other Long Term Liabilities
n/a
11 10603000
10 9942000
51 50611000
36 35711000
Accrued Liabilities
n/a
0 0
0 0
0 0
0 0
Pension Liabilities
n/a
0 0
0 0
0 0
0 0
Pensions
n/a
0 0
0 0
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
7 7258000
7 7123000
49 48628000
31 31268000
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
3 3345000
3 2819000
2 1983000
4 4443000
Total Noncurrent Liabilities
n/a
11 10603000
10 9942000
51 50611000
36 35711000
Total Liabilities
n/a
24 23687000
24 23765000
70 70426000
115 115079000
Preferred Equity
n/a
0 0
0 0
0 0
0 0
Share Capital & Additional Paid-In Capital
n/a
7 6817000
210 209597000
274 274202000
373 372631000
Common Stock
n/a
0 0
0 0
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
0 0
0 0
Other Share Capital
n/a
0 0
0 0
0 0
0 0
Treasury Stock
n/a
0 0
0 0
0 0
0 0
Retained Earnings
n/a
-123 -122702000
-152 -151574000
-189 -188998000
61 60649000
Other Equity
n/a
0 7000
0 3000
0 1000
0 -74000
Equity Before Minority Interest
n/a
-116 -115878000
58 58026000
85 85205000
433 433206000
Minority Interest
n/a
0 0
0 0
0 0
0 0
Total Equity
n/a
-116 -115878000
58 58026000
85 85205000
433 433206000
Total Liabilities & Equity
n/a
-92 -92191000
82 81791000
156 155631000
548 548285000
Remarks restated on n/a restated on Mar 26, 2014 n/a restated on Mar 18, 2015 n/a restated on Mar 11, 2016 n/a restated on Nov 4, 2016 n/a
Cash Flow StatementCF data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '11FY '12FY '13FY '14FY '15
Net Income/Starting Line
20
-28
-29
-37
250
Net Income
0
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
0
Other Adjustments
0
0
0
0
0
Depreciation & Amortization
2
2
2
2
2
Non-Cash Items
4
2
2
5
2
Stock-Based Compensation
0
0
0
0
0
Deferred Income Taxes
0
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
0
Change in Working Capital
-2
5
0
46
36
(Increase) Decrease in Accounts Receivable
0
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
0
0
Cash from Operating Activities
23
-18
-25
15
289
Change in Fixed Assets & Intangibles
-1
-1
-1
-2
-2
Disposition of Fixed Assets & Intangibles
0
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
0
Net Change in Long Term Investment
-26
19
-41
-68
-236
Decrease in Long Term Investment
0
0
0
0
0
Increase in Long Term Investment
0
0
0
0
0
Net Cash From Acquisitions & Divestitures
0
0
0
0
0
Net Cash from Divestitures
0
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
0
Cash for Joint Ventures
0
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
0
Other Investing Activities
0
0
0
0
0
Net Cash From Discontinued Operations (investing)
0
0
0
0
0
Cash from Investing Activities
-27
19
-42
-69
-238
Dividends Paid
0
0
0
0
0
Cash From (Repayment of) Debt
0
0
0
0
0
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
0
Cash From Long Term Debt
0
0
0
0
0
Cash From (Repurchase of) Equity
0
7
64
61
84
Increase in Capital Stock
0
7
64
61
84
Decrease in Capital Stock
0
0
0
0
0
Other Financing Activities
0
0
0
0
0
Net Cash From Discontinued Operations (financing)
0
0
0
0
0
Cash from Financing Activities
0
7
64
61
84
Net Cash Before Disc. Operations and FX
-4
7
-3
7
135
Change in Cash from Disc. Operations and Other
0
0
0
0
0
Net Cash Before FX
-4
7
-3
7
135
Effect of Foreign Exchange Rates
0
0
0
0
0
Net Changes in Cash
-4
7
-3
7
135
Remarks
restated on Mar 26, 2014 n/a
calculated values,
restated on Mar 18, 2015 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo